全文获取类型
收费全文 | 8467篇 |
免费 | 507篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 108篇 |
儿科学 | 361篇 |
妇产科学 | 345篇 |
基础医学 | 1100篇 |
口腔科学 | 158篇 |
临床医学 | 708篇 |
内科学 | 2017篇 |
皮肤病学 | 142篇 |
神经病学 | 681篇 |
特种医学 | 420篇 |
外科学 | 1219篇 |
综合类 | 38篇 |
预防医学 | 559篇 |
眼科学 | 164篇 |
药学 | 516篇 |
中国医学 | 39篇 |
肿瘤学 | 419篇 |
出版年
2023年 | 27篇 |
2021年 | 101篇 |
2020年 | 74篇 |
2019年 | 122篇 |
2018年 | 150篇 |
2017年 | 99篇 |
2016年 | 107篇 |
2015年 | 158篇 |
2014年 | 215篇 |
2013年 | 250篇 |
2012年 | 350篇 |
2011年 | 375篇 |
2010年 | 226篇 |
2009年 | 219篇 |
2008年 | 430篇 |
2007年 | 470篇 |
2006年 | 473篇 |
2005年 | 445篇 |
2004年 | 435篇 |
2003年 | 397篇 |
2002年 | 423篇 |
2001年 | 347篇 |
2000年 | 374篇 |
1999年 | 294篇 |
1998年 | 135篇 |
1997年 | 118篇 |
1996年 | 129篇 |
1995年 | 113篇 |
1994年 | 98篇 |
1993年 | 106篇 |
1992年 | 185篇 |
1991年 | 159篇 |
1990年 | 136篇 |
1989年 | 131篇 |
1988年 | 132篇 |
1987年 | 138篇 |
1986年 | 103篇 |
1985年 | 90篇 |
1984年 | 63篇 |
1983年 | 47篇 |
1982年 | 48篇 |
1981年 | 42篇 |
1979年 | 32篇 |
1977年 | 28篇 |
1976年 | 26篇 |
1975年 | 24篇 |
1973年 | 24篇 |
1970年 | 31篇 |
1969年 | 22篇 |
1968年 | 35篇 |
排序方式: 共有8994条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Jessica L. Petrick Andrea A. Florio Ariana Znaor David Ruggieri Mathieu Laversanne Christian S. Alvarez Jacques Ferlay Patricia C. Valery Freddie Bray Katherine A. McGlynn 《International journal of cancer. Journal international du cancer》2020,147(2):317-330
Primary liver cancer, the major histology of which is hepatocellular carcinoma (HCC), is the second leading cause of cancer death worldwide. We comprehensively examined recent international trends of primary liver cancer and HCC incidence using population-based cancer registry data. Incidence for all primary liver cancer and for HCC by calendar time and birth cohort was examined for selected countries between 1978 and 2012. For each successive 5-year period, age-standardized incidence rates were calculated from Volumes V to XI of the Cancer Incidence in Five Continents (CI5) series using the online electronic databases, CI5plus. Large variations persist in liver cancer incidence globally. Rates of liver cancer remain highest in Asian countries, specifically in the East and South-East, and Italy. However, rates in these high-risk countries have been decreasing in recent years. Rates in India and in most countries of Europe, the Americas and Oceania are rising. As the population seroprevalence of hepatitis B virus (HBV) continues to decline, we anticipate rates of HCC in many high-risk countries will continue to decrease. Treatment of hepatitis C virus (HCV) is likely to bring down rates further in some high-rate, as well as low-rate, countries with access to effective therapies. However, such gains in the control of liver cancer are at risk of being reversed by the growing obesity and diabetes epidemics, suggesting diabetes treatment and primary prevention of obesity will be key in reducing liver cancer in the longer-term. 相似文献
5.
José Luis R Martin Víctor Pérez Montse Sacristán Fernando Rodríguez-Artalejo Cristóbal Martínez Enric Alvarez 《European psychiatry》2006,21(1):11-20
OBJECTIVE: To assess antipsychotic medication in the treatment of schizophrenia, based on trial drop-out rates. METHOD: The studies included were randomised controlled trials that compared any of the four clinically best-established atypical antipsychotics (quetiapine, olanzapine, risperidone or clozapine) against either of two typical antipsychotics regarded as the gold standard (haloperidol or chlorpromazine). RESULTS: Meta-analysis indicated less risk of all-cause patient withdrawal from atypical medication trials where dosage was flexible, in both the short, relative risk (RR) 0.70 (95% CI 0.64-0.76), P<0.00001, and long term, RR 0.72 (0.65-0.80), P<0.00001. Similar results were observed for withdrawal due to adverse events, RR: 0.54 (0.41-0.72), P<0.0001. Nevertheless, the favourable effects of atypical medication disappeared in trials relying on fixed dosage. CONCLUSIONS: We detected a significant positive effect in terms of the outcome of treatment discontinuation for atypical versus typical medication, though only where the use of flexible rather than fixed doses (closer to an experimental control situation) was possible. 相似文献
6.
Computed tomographic (CT) scans of the brain in a child with Smith-Lemli-Opitz syndrome revealed enlargement of the ventricular system, hypoplasia of the cerebellum, and abnormal thickening of the gray matter, consistent with pachygyria. These findings have been previously noted in autopsies performed on patients with this disorder. We conclude that CT scanning is a valuable tool in the evaluation of children suspected of having the Smith-Lemli-Opitz syndrome. 相似文献
7.
T López-Alburquerque A García Miguel J J Ruiz Ezquerro J de Portugal Alvarez 《Journal of neurology, neurosurgery, and psychiatry》1987,50(4):428-434
The nerve action potential at the elbow and somatosensory evoked potentials (SEPs) at the scalp were recorded over 30 minutes of tourniquet-induced limb ischaemia in 10 diabetic patients and 10 controls. According to the SEP changes, an increased resistance to nerve ischaemia in diabetic patients was observed. The pathways involved in SEP conduction are discussed. 相似文献
8.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
9.
10.